Despite its widespread usage and efficacy reported in various studies, anti-VEGF injections pose a risk of development of traction resulting in retinal detachment and vitreoretinal fibrosis, which has been reported by Ramasubramaniam et al., in their study, and who advised cautious use of intravitreal Bevacizumab in Coats’ disease with exudative detachment in any age group [28]. Here, VEGFA is linked to Coats disease.